BioSpace News Archive

Mirati’s adagrasib demonstrated a solid safety profile in new data released Monday. Despite this, the company’s stock fell 8% in after-hours trading.

Topline results from the Phase II TORREY study showed Gossamer Bio’s seralutinib met its primary efficacy endpoint in pulmonary arterial hypertension.

Entact Bio launched with $81 million Tuesday to advance its protein enhancement platform.

Editas Medicine released positive proof of concept data Tuesday morning from the first patients dosed with its experimental CRISPR-based gene therapy for sickle cell disease.

MEI Pharma, Inc. will have a strategic realignment that would see at least 30% of its workforce laid off and a pivot towards two of its earlier clinical-stage assets.

Mindset Pharma Inc. today announced that James Lanthier, CEO of Mindset, and Joseph Araujo, CSO, will participate in two upcoming conferences.

Agios Pharmaceuticals, Inc. today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023.

Lucira Health, Inc. and Loch Lomond Villa announced today a clinical study to simultaneously test residents, medical and support staff, and visitors for COVID-19 and Influenza A/B infection with the Lucira COVID-19 & Flu Test.

OnKure, Inc. today announced the appointment of Roberta (“Robbie”) Alton, Pharm., as Vice President of Clinical Operations.

Daewoong Pharmaceutical (CEO Jeon Sengho, Lee Changjae), a global healthcare company, announced on 5th that its “Envlo 0.3mg”, a new sodium-glucose cotransporters 2 inhibitor (SGLT2) developed to treat type 2 diabetes mellitus obtained a product license from the Ministry of Food and Drug Safety on November 30.